放疗前微创卵巢移位术在年轻中晚期宫颈癌患者中的应用

摘要

目的:探讨放疗前微创卵巢移位术对行放射治疗年轻中晚期宫颈癌患者性激素水平、卵巢功能及生存率的影响.方法:研究对象选取我院2010年3月至2016年3月收治的年轻中晚期宫颈癌患者共110例,以随机数字表法分为对照组(55例)和观察组(55例),对照组直接行放化疗治疗,观察组行微创卵巢移位术后开始放化疗治疗;比较两组患者治疗前后E2、FSH、LH水平,治疗后Kupperman评分,卵巢功能影响情况,随访生存率及复发率等.结果:两组患者治疗前性激素水平均显著优于治疗后(P<0.05);观察组患者治疗后E2、FSH及LH水平均显著优于对照组(P<0.05);观察组患者治疗后Kupperman评分显著低于对照组(P<0.05);观察组患者卵巢功能影响情况显著优于对照组(P<0.05);同时两组患者生存率和复发率比较差异无统计学意义(P>0.05).结论:年轻中晚期宫颈癌患者于放疗前行微创卵巢移位术可有效保护卵巢功能,调节性激素水平,缓解围绝经期症状,且未对生存时间和复发风险产生不利影响.%Objective:To investigate the influence of minimally invasive ovarian pre-shift on sex hormone levels, ovarian function and survival rate of young patients with advanced cervical cancer by radiotherapy. Methods:110 young patients with advanced cervical cancer were chosen in the period from March 2010 to March 2016 in our hospi-tal and randomly divided into two groups including control group(55 patients)with chemoradiotherapy used alone and observation group(55 patients)with minimally invasive ovarian pre-shift combined with chemoradiotherapy, and the levels of E2,FSH and LH before and after treatment,the Kupperman score after treatment,the influence of o-varian function,the survival rate and recurrence rate with follow-up of both groups were compared.Results:The lev-els of E2,FSH and LH before treatment of both groups were significant better than post-treatment(P<0.05).The levels of E2,FSH and LH after treatment of observation group were significant better than control group(P<0.05). The Kupperman score after treatment of control group was significant higher than observation group(P<0.05).The influence of ovarian function of observation group was significant higher than control group(P<0.05).There was no significant difference in the survival rate and recurrence rate between 2 groups(P>0.05).Conclusion:Minimally invasive ovarian pre-shift in the treatment of young patients with advanced cervical cancer by radiotherapy can effi-ciently regulate the sex hormone levels,relieve the menopause symptoms,protect ovarian function and not have nega-tive impact on the survival time and recurrence risk.